Learn what PROTACs (proteolysis-targeting chimeras) are, how they work via the ubiquitin–proteasome system, and why protein degraders can outperform traditional small molecule inhibitors in oncology and beyond.
Learn how PROTACs (Proteolysis Targeting Chimeras) and targeted protein degraders are transforming small molecule drug design by eliminating disease-causing proteins, enabling catalytic, durable pharmacology across oncology, immunology, and other therapeutic areas.
Discover how molecular glues are transforming drug discovery by enabling targeted protein degradation of previously “undruggable” targets. Learn their mechanism, advantages over PROTACs, and emerging AI‑driven design strategies in oncology and immunology.
Discover how oral small molecule GLP‑1 receptor agonists could replace weekly injections like semaglutide and tirzepatide, offering scalable, room‑temperature‑stable pills that transform obesity and type 2 diabetes care worldwide.
Discover how next‑generation mitochondrial uncouplers boost resting energy expenditure, burn liver and visceral fat, and improve insulin sensitivity by turning excess calories into heat instead of stored fat. Learn why this emerging obesity and NAFLD treatment could complement today’s appetite‑suppressing drugs.
Discover how oral GLP‑1 small molecule drugs could transform obesity and type 2 diabetes treatment. Learn how they work, why they may be cheaper and easier than injectables, and their potential to become “statins” for metabolic disease.
Learn how targeted protein degradation (TPD) uses PROTACs and molecular glue degraders to hijack the ubiquitin–proteasome system, eliminate disease-causing proteins, and expand the “druggable” proteome beyond traditional small molecule inhibitors.
Discover why KRAS was historically labeled “undruggable,” how covalent KRAS G12C inhibitors like sotorasib and adagrasib overcame structural challenges, and what this breakthrough means for treating KRAS-mutant cancers such as NSCLC, colorectal, and pancreatic tumors.
Learn what AI-designed small molecule drugs are and how AI and machine learning are revolutionizing oral drug discovery, from de novo molecular design and multi-parameter optimization to faster, safer clinical candidates.
Discover why small molecule antivirals are entering a new golden age. Learn how next-generation oral antivirals targeting viral polymerases and proteases are reshaping treatment for COVID-19, RSV, and emerging viral threats.